

7.01.151	Prostatic Urethral Lift		
Original Policy Date:	April 30, 2015	Effective Date:	October 1, 2023
Section:	7.0 Surgery	Page:	Page 1 of 33

Policy Statement

- I. Use of prostatic urethral lift in individuals with moderate-to-severe lower urinary tract obstruction due to benign prostatic hyperplasia may be considered **medically necessary** when **all** of the following criteria are met:
 - A. The individual has persistent or progressive lower urinary tract symptoms despite medical therapy (α_1 -adrenergic antagonists maximally titrated, 5 α -reductase inhibitors, or combination medication therapy maximally titrated) over a trial period of no less than 6 months, or is unable to tolerate medical therapy
 - B. Prostate gland volume is less than or equal to 80 mL
 - C. Prostate anatomy demonstrates normal bladder neck without an obstructive or protruding median lobe
 - D. Individual does not have urinary retention related to conditions other than benign prostatic hyperplasia, urinary tract infection, or recent prostatitis (within past year)
 - E. Individual has had appropriate testing to exclude diagnosis of prostate cancer
 - F. Individual does not have a known allergy to nickel, titanium or stainless steel

- II. Use of prostatic urethral lift in **all** other situations, including repeat procedures, is considered **investigational**.

NOTE: Refer to [Appendix A](#) to see the policy statement changes (if any) from the previous version.

Policy Guidelines

Use of temporarily implanted nitinol devices for benign prostatic hyperplasia is addressed separately in Blue Shield of California Medical Policy: Temporarily Implanted Nitinol Device (iTind) for Benign Prostatic Hyperplasia.

Description

Benign prostatic hyperplasia (BPH) is a common condition in older individuals that can lead to increased urinary frequency, an urgency to urinate, a hesitancy to urinate, nocturia, and a weak stream when urinating. The prostatic urethral lift (PUL) procedure involves the insertion of one or more permanent implants into the prostate, which retracts prostatic tissue and maintains an expanded urethral lumen.

Use of temporarily implanted nitinol devices for benign prostatic hyperplasia is addressed separately in Blue Shield of California Medical Policy: Temporarily Implanted Nitinol Device (iTind) for Benign Prostatic Hyperplasia.

Related Policies

- Temporarily Implanted Nitinol Device (iTind) for Benign Prostatic Hyperplasia
- Transurethral Water Vapor Thermal Therapy and Transurethral Water Jet Ablation (Aquablation) for Benign Prostatic Hypertrophy

Benefit Application

Benefit determinations should be based in all cases on the applicable contract language. To the extent there are any conflicts between these guidelines and the contract language, the contract language will control. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Some state or federal mandates (e.g., Federal Employee Program [FEP]) prohibits plans from denying Food and Drug Administration (FDA)-approved technologies as investigational. In these instances, plans may have to consider the coverage eligibility of FDA-approved technologies on the basis of medical necessity alone.

Regulatory Status

One implantable transprostatic tissue retractor system has been cleared for marketing by the U.S. Food and Drug Administration (FDA) through the 510(k) process. In 2013, the NeoTract UroLift[®] System UL400 (NeoTract) was cleared (after receiving clearance through the FDA's de novo classification process in March 2013; K130651/DEN130023). In 2016, the FDA determined that the UL500 was substantially equivalent to existing devices (UL400) for the treatment of symptoms of urinary flow obstruction secondary to BPH in individuals ages 50 years and older. In 2017, the FDA expanded the indication for the UL400 and UL500 to include *lateral and median* lobe hyperplasia in men 45 years or older. An additional clearance in 2019 (K193269) modified an existing contraindication for use from men with a prostate volume of >80 cc to men with a prostate volume of >100 cc. FDA product code: PEW.

Rationale

Background

Benign Prostatic Hyperplasia

Benign prostatic hyperplasia (BPH) is a common disorder among older individuals that results from hyperplastic nodules in the periurethral or transitional zone of the prostate. The clinical manifestations of BPH include increased urinary frequency, nocturia, urgency or hesitancy to urinate, and a weak stream when urinating. The urinary tract symptoms often progress with worsening hypertrophy and may lead to acute urinary retention, incontinence, renal insufficiency, and/or urinary tract infection. Benign prostatic hyperplasia prevalence increases with age and is present in more than 80% of individuals ages 70 to 79 years.¹

Two scores are widely used to evaluate BPH-related symptoms: the American Urological Association Symptom Index (AUASI) and the International Prostate Symptom Score (IPSS). The AUASI is a self-administered 7-item questionnaire assessing the severity of various urinary symptoms.² Total AUASI scores range from 0 to 35, with overall severity categorized as mild (≤ 7), moderate (8-19), or severe (20-35).¹ The IPSS incorporates questions from the AUASI and a quality of life question or a "Bother score."³

Evaluation and management of BPH include assessment for other causes of lower urinary tract dysfunction (e.g., prostate cancer), symptom severity, and the degree that symptoms are bothersome to determine the therapeutic approach.

For patients with moderate-to-severe symptoms (e.g., an AUASI score of ≥ 8), bothersome symptoms, or both, a discussion about medical therapy is reasonable. Benign prostatic hyperplasia should generally be treated medically first. Available medical therapies for BPH-related lower urinary tract dysfunction include α -adrenergic blockers (e.g., alfuzosin, doxazosin, tamsulosin, terazosin, silodosin), 5 α -reductase inhibitors (e.g., finasteride, dutasteride), combination α -adrenergic blockers and 5 α -

reductase inhibitors, anti-muscarinic agents (e.g., darifenacin, solifenacin, oxybutynin), and phosphodiesterase-5 inhibitors (e.g., tadalafil).¹ In a meta-analysis of both indirect comparisons from placebo-controlled studies (including 6,333 patients) and direct comparative studies (including 507 patients), Djavan et al (1999) found that the IPSS improved by 30% to 40% and the Qmax score (mean peak urinary flow rate) improved by 16% to 25% in individuals assigned to α -adrenergic blockers.⁴ Combination therapy using an α -adrenergic blocker and 5 α -reductase inhibitor has been shown to be more effective for improving IPSS than either treatment alone, with median scores improving by more than 40% over 1 year and by more than 45% over 4 years.

Patients who do not have sufficient response to medical therapy, or who are experiencing significant side effects with medical therapy, may be referred for surgical or ablative therapies. Various surgical and ablative procedures are used to treat BPH. Transurethral resection of the prostate (TURP) is generally considered the reference standard for comparisons of BPH procedures.⁵ In the perioperative period, TURP is associated with risks of any operative procedure (e.g., anesthesia risks, blood loss). Although short-term mortality risks are generally low, a large prospective study with 10,654 patients by Reich et al (2008) reported the following short-term complications: "failure to void (5.8%), surgical revision (5.6%), significant urinary tract infection (3.6%), bleeding requiring transfusions (2.9%), and transurethral resection syndrome (1.4%)."⁶ Incidental carcinoma of the prostate was diagnosed by histologic examination in 9.8% of patients. In the longer term, TURP is associated with an increased risk of sexual dysfunction and incontinence.

Several minimally invasive prostate ablation procedures are available, including transurethral microwave thermotherapy, transurethral needle ablation of the prostate, urethromicroablation phototherapy, and photoselective vaporization of the prostate. The minimally invasive procedures were individually compared with TURP at the time they were developed, which provided a general benchmark for evaluating those procedures. The American Urological Association (AUA) recommends surgical intervention for patients who have "renal insufficiency secondary to BPH, refractory urinary retention secondary to BPH, recurrent urinary tract infections (UTIs), recurrent bladder stones or gross hematuria due to BPH, and/or with lower urinary tract symptoms (LUTS) attributed to BPH refractory to and/or unwilling to use other therapies."⁷

Literature Review

Evidence reviews assess the clinical evidence to determine whether the use of technology improves the net health outcome. Broadly defined, health outcomes are the length of life, quality of life, and ability to function—including benefits and harms. Every clinical condition has specific outcomes that are important to patients and managing the course of that condition. Validated outcome measures are necessary to ascertain whether a condition improves or worsens; and whether the magnitude of that change is clinically significant. The net health outcome is a balance of benefits and harms.

To assess whether the evidence is sufficient to draw conclusions about the net health outcome of technology, 2 domains are examined: the relevance, and quality and credibility. To be relevant, studies must represent 1 or more intended clinical use of the technology in the intended population and compare an effective and appropriate alternative at a comparable intensity. For some conditions, the alternative will be supportive care or surveillance. The quality and credibility of the evidence depend on study design and conduct, minimizing bias and confounding that can generate incorrect findings. The randomized controlled trial (RCT) is preferred to assess efficacy; however, in some circumstances, nonrandomized studies may be adequate. Randomized controlled trials are rarely large enough or long enough to capture less common adverse events and long-term effects. Other types of studies can be used for these purposes and to assess generalizability to broader clinical populations and settings of clinical practice.

Promotion of greater diversity and inclusion in clinical research of historically marginalized groups (e.g., People of Color [African-American, Asian, Black, Latino and Native American]; LGBTQIA (Lesbian, Gay, Bisexual, Transgender, Queer, Intersex, Asexual); Women; and People with Disabilities

[Physical and Invisible]) allows policy populations to be more reflective of and findings more applicable to our diverse members. While we also strive to use inclusive language related to these groups in our policies, use of gender-specific nouns (e.g., women, men, sisters, etc.) will continue when reflective of language used in publications describing study populations.

Prostatic Urethral Lift

Clinical Context and Therapy Purpose

The purpose of prostatic urethral lift (PUL) in individuals who have lower urinary tract symptoms due to benign prostatic hyperplasia (BPH) is to provide a treatment option that is an alternative to or an improvement on existing therapies such as medical management or transurethral resection of the prostate (TURP).

The following PICO was used to select literature to inform this review.

Populations

The relevant population of interest is men who are experiencing lower urinary tract symptoms without a history suggesting non-BPH causes of the symptoms and who do not have a sufficient response to medical therapy or are experiencing significant side effects with medical therapy.

Interventions

The therapy being considered is PUL. The PUL procedure involves the placement of 1 or more implants in lobes of the prostate using a transurethral delivery device. The implant device is designed to retract the prostate to allow expansion of the prostatic urethra. The implants are retained in the prostate to maintain an expanded urethral lumen. One device, the NeoTract UroLift System, has been cleared for marketing by the FDA (see Regulatory Status section). The device has 2 main components: the delivery device and the implant. Each delivery device comes preloaded with a UroLift implant.

Comparators

The following practices are currently being used to treat BPH in this setting: TURP is generally considered the reference standard for comparisons of BPH procedures. Several minimally invasive prostate ablation procedures have also been developed, including transurethral microwave thermotherapy, transurethral needle ablation of the prostate, urethromicroablation phototherapy, and photoselective vaporization of the prostate.

Outcomes

A number of health status measures are used to evaluate symptoms relevant to BPH and adverse events of treatment for BPH, including urinary symptoms, urinary dysfunction measured by urinary flow rate (Q_{max}), ejaculatory dysfunction, overall sexual health, and overall quality of life. Q_{max} is measured by uroflowmetry; low rates are associated with more voiding dysfunction and rates <10 mL/sec are considered obstructed.

Outcomes data demonstrating durability to at least 2 years is preferred.

Some validated patient-reported scales are shown in Table 1.

Of note, the prostate volume does not have a direct correlation with the severity of urinary symptoms.⁸

Table 1. Patient-Reported Health Outcome Measures Relevant to Benign Prostatic Hyperplasia

Measure	Outcome Evaluated	Description	Clinically Meaningful Difference (If Known)
Male Sexual Health Questionnaire for	Ejaculatory function and quality of life	Patient-administered, 4-item scale.	NR

Measure	Outcome Evaluated	Description	Clinically Meaningful Difference (If Known)
Ejaculatory Dysfunction ⁹		Symptoms rated as absent (15) to severe (0). QOL assessed as no problem (0) to extremely bothered (5).	
Sexual Health Inventory for Men ¹⁰	Erectile function	Patient-administered, 5-item scale. Erectile dysfunction rated as severe (1-7), moderate (8-11), mild to moderate (12-16), or mild (17-21). Fewest symptoms present for patients with scores 22-25.	5-point change ¹¹ .
American Urological Association Symptom Index; International Prostate Symptom Score ^{1,3,12}	Severity of lower urinary tract symptoms	Patient-administered, 7-item scale. Symptoms rated as mild (0-7), moderate (8-19), or severe (20-35). IPSS asks an additional question, rating QOL as delighted (0) to terrible (6)	<ul style="list-style-type: none"> • Minimum of 3-point change^{12,1}. • Minimum of 30% change¹³.
Benign Prostatic Hyperplasia Impact Index ^{14,2}	Effect of urinary symptoms on health domains	Patient-administered, 4-item scale. Symptoms rated as absent (0) to severe (13).	Minimum of 0.4-point change ¹² .

IPSS: International Prostate Symptom Score; QOL: quality of life; NR: Not reported.

Study Selection Criteria

Methodologically credible studies were selected using the following principles:

- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
- To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- Studies with duplicative or overlapping populations were excluded.

Review of Evidence Systematic Reviews

Initial Prostatic Urethral Lift Procedure

Several systematic reviews on PUL have been published. They include a similar set of trials and noncomparative studies. The overlap of studies is shown in Appendix Table 3. Perera et al (2015) reported on the results of a systematic review and meta-analysis¹⁵ of studies reporting outcomes after the PUL procedure, which included 7 prospective cohort studies,^{16,17,18,19,20,21,22} a crossover study¹⁶, and the LIFT RCT.²³

Shore (2015)²⁴ performed a systematic review of UroLift studies, which included the LIFT RCT²³; Roehrborn et al [2015]²⁵; McVary et al [2014]²⁶), a crossover study¹⁶), and 4 prospective cohort studies (Garrido Abad et al [2013]²⁷; Chin et al [2012]¹⁹; Woo et al [2012]²⁰; McNicholas et al [2013]¹⁸).

Jones et al (2016) performed a systematic review of UroLift studies with at least 12 months of follow-up.²⁸ Seven studies were identified, which included 4 noncomparative studies (Woo et al [2011],²¹ Chin et al [2012],¹⁹ McNicholas et al [2013],¹⁸ Bozkurt et al [2016]²⁹), a crossover study¹⁶), and 2 RCTs (LIFT²³ and BPH6¹¹).

The National Institute for Health and Care Excellence (2016) published a technical guidance on prostatic lift procedures.³⁰ The Institute performed a literature search and data synthesis to support the development of the guidance. Studies selected were the same studies included in Perera et al (2015),¹⁵ except for the exclusion of Hoffman et al (2012)²² in the analysis.

Tanneru et al (2020) published a systematic review and meta-analysis of studies with at least 24 months of follow-up.³¹ Five studies were included; 3 noncomparative studies (Chin et al [2012]¹⁹, Rukstalis (2016)³², Sievert et al [2020]³³, and 2 RCTs (LIFT and BPH6).

Perera et al (2015), Shore (2015), Jones et al (2016) and Tanneru et al (2020) analyzed data from the PUL arms of the studies only and the National Institute for Health and Care Excellence review was published before the BPH6 RCT. Therefore, these systematic reviews will not be discussed further.

Jung et al (2019) published a Cochrane systematic review of PUL parallel-group RCTs published up to Jan 2019.³⁴ The 2 included RCTs (N=297) were the LIFT and BPH6 trials described in detail in the following section.^{23,35} The 2 RCTs included different comparators and results were not combined meta-analytically. The authors used the GRADE approach to rate the certainty of the evidence. The conclusions were as follows:

- PUL appears less effective than TURP in improving urological symptoms, both in the short-term and long-term (low-certainty evidence);
- PUL may result in a similar quality of life compared to TURP (low-certainty evidence);
- PUL may result in similar erectile function compared to TURP (moderate-certainty evidence);
- PUL may result in better ejaculatory function compared to TURP (moderate-certainty evidence);
- Rates of major adverse events are unclear (very low-certainty evidence);
- Rates of retreatment are unclear (very low-certainty evidence).

In 2022, Franco et al published a Cochrane network meta-analysis assessing the comparative effectiveness of minimally invasive treatments for lower urinary tract symptoms in men with BPH.³⁶ Twenty-seven trials representing 3017 men were included through February 2021. Compared to TURP, PUL and prostatic arterial embolization (PAE) were found to result in little to no difference in urological symptoms, while convective water vapor thermal therapy (e.g., Rezum), transurethral microwave thermotherapy (TUMT), and temporary implantable nitinol devices (TIND) may result in worse urological outcomes. While minimally invasive treatments were found to result in little to no

difference in quality of life compared to TURP, they were found to result in a large reduction in major adverse events. The overall certainty of the evidence according to GRADE criteria was low to very low across these outcomes. The authors were uncertain of the effects of PUL on erectile function (mean difference of International Index of Erectile Function, 3.00; 95% CI, -5.45 to 11.44), ejaculatory dysfunction (RR 0.05; 95% CI, 0.00 to 1.06), and retreatment rates (RR 2.39; 95% confidence interval [CI], 0.5 to 11.1) compared to TURP. Retreatment was defined as the number of participants requiring a follow-up procedure for lower urinary tract symptoms with another minimally invasive treatment or TURP, excluding follow-up procedures to treat complications, which were evaluated as major adverse events.

Randomized Controlled Trials

Two RCTs of PUL have been performed. Key trial characteristics and study results are shown below in Tables 2, 3, 6, and 7. Additionally, a brief description of each trial is provided in the following sections.

Table 2. Prostatic Urethral Lift Randomized Controlled Trial Characteristics

Study; Trial	Countries	Sites	Dates	Inclusion Criteria	Interventions, n	
					Baseline Prostate Volume, cm ³	Active Comparator
Sonksen et al (2015)¹¹; BPH6	Denmark, Germany, U.K.	10	Feb 2012- Oct 2013	Age ≥50 y, IPSS >12, prostate volume ≤60 cm ³ , without median lobe obstruction	16-59	PUL=46 TURP=45
Roehrborn et al (2013)²³; LIFT	U.S., Canada, Australia	19	Feb-Dec 2011	Age ≥50 y, IPSS ≥13, prostate volume 30-80 cm ³ , washed out of BPH medications, without median lobe obstruction	30-77	PUL=140 Sham=66

BPH: benign prostatic hyperplasia; IPSS: International Prostate Symptom Score; PUL: prostatic urethral lift; TURP: transurethral resection of the prostate.

BPH6 Study

Sonksen et al (2015) reported on the results of a multicenter RCT comparing the PUL procedure with TURP among individuals ages 50 and older with lower urinary tract symptoms, secondary to benign prostatic obstruction.¹¹ Eligible patients had an International Prostate Symptom Score (IPSS) above 12, a Qmax of 15 mL/s or less for a 125-mL voided volume, a postvoid residual volume less than 350 mL, and prostate volume of 60 cm³ or less on ultrasound. Patients were excluded if there was a median lobe obstruction in the prostate or signs of active infection. The trial used a novel composite endpoint, referred to as the BPH6, which included the following criteria:

- Lower urinary tract symptom relief: Reduction in IPSS by ≥30% within 12 months, relative to baseline
- Recovery experience: Self-assessed by patients as ≥70% within 1 month, using a visual analog scale
- Erectile function: Reduction in Sexual Health Inventory for Men (SHIM) score by ≤6 points within 12 months, relative to baseline
- Ejaculatory function: Emission of semen as assessed by question 3 in the Male Sexual Health Questionnaire for Ejaculatory Dysfunction (MSHQ-EjD)
- Continence preservation: Incontinence Severity Index ≤4 points at all follow-up visits
- Safety: No treatment-related adverse events exceeding grade 1 on the Clavien-Dindo classification system at time of procedure or any follow-up.

Patients were considered treatment responders if they met all 6 composite criteria. While this composite endpoint has not been previously validated, core components of the composite score have been independently validated in a clinical setting. The trial used a noninferiority design with a margin

of 10% for the primary endpoint, BPH6. Study investigators modified 2 of the original endpoint definitions in the study's analysis, including changing the sexual function element assessment from a single time point (12 months) to assess sustained effects during 12 months of follow-up, and lowering the threshold of quality of recovery on a visual analog scale from 80 to 70.

Table 3. Summary of Evidence From the BPH6 Study

Outcomes	3 Months		12 Months		24 Months	
	PUL	TURP	PUL	TURP	PUL	TURP
<i>Mean change in IPSS</i>						
n	42	34	40	32	37	32
Mean (SD)	-11.7 (8.5)	-11.8 (9.5)	-10.9 (7.9)	-15.4 (6.8)	-9.2 (9.2)	-15.3 (7.5)
p	<.001	<.001	<.001	<.001	<.001	<.001
Comparison (p)	.978		.013		.004	
<i>Change in IPSS QOL</i>						
n	43	34	40	32	37	32
Mean (SD)	-2.6 (1.7)	-2.4 (2.0)	-2.8 (1.8)	-3.1 (1.6)	-2.5 (1.8)	-3.3 (1.6)
p	<.001	<.001	<.001	<.001	<.001	<.001
Comparison (p)	.55		.436		.066	
<i>Change in Qmax</i>						
n	33	25	32	29	27	27
Mean (SD)	4.2 (5.0)	12.7 (9.8)	4.0 (4.8)	13.7 (10.4)	5.0 (5.5)	15.8 (16.5)
p	<.001	.003	<.001	.003	<.001	.002
Comparison (p)	<.001		<.001		.002	
<i>Change in SHIM score</i>						
n	38	27	32	27	29	28
Mean (SD)	-0.7 (5.2)	-1.0 (5.2)	-0.1 (4.7)	-0.9 (4.3)	-0.2 (4.3)	-1.8 (4.90)
p	.386	.328	.940	.29	.832	.067
Comparison (p)	.861		.486		.201	
<i>Change in MSHQ-EjD function score</i>						
n	38	27	32	27	29	27
Mean (SD)	-0.7 (2.1)	-3.0 (4.1)	1.3 (3.3)	-3.7 (4.1)	0.3 (3.4)	-4.0 (4.6)
p	.251	<.001		<.001	.666	<.001
Comparison (p)	<.001		<.001		<.001	
<i>Change in MSHQ-EjD bother score</i>						
n	38	28	32	27	29	27
Mean (SD)	-0.7 (2.1)	0.2 (1.5)	0.5 (2.2)	0.0 (1.5)	-0.1 (2.2)	-0.3 (1.9)
p	.062	.470	.214	.896	.734	.415
Comparison (p)	.069		.359		.771	
<i>Composite score</i>	NR	NR	Response: 52%	Response: 20%	NR	NR
Comparison (95% CI); p	NR		Difference: 32%(10% to 51%);.005		NR	
<i>Clavien-Dindo adverse events</i>						
Grade 1, n (%)	NR	NR	30 (68)	26 (74)	NR	NR
Adverse events			60	79		
Grade 2, n (%)	NR	NR	3 (7)	4 (11)	NR	NR
Adverse events			3	5		
Grade 3, n (%)	NR	NR	4 (9)	5 (14)	NR	NR
Adverse events			4	5		

Adapted from Gratzke et al (2017).³⁵

BPH: benign prostatic hyperplasia; CI: confidence interval; IPSS: International Prostate Symptom Score; MSHQ-EjD: Male Sexual Health Questionnaire for Ejaculatory Dysfunction; NR: not reported; PUL: prostatic urethral lift; Qmax: mean peak urinary flow rate; QOL: quality of life; SD: standard deviation; SHIM: Sexual Health Inventory for Men; TURP: transurethral resection of the prostate.

Ninety-one patients were randomized to TURP (n=45) or PUL (n=46). Ten patients in the TURP group and 1 patient in the PUL group declined treatment, leaving an analysis group of 80 subjects. The analysis was per-protocol, including 35 in the TURP group and 44 in the PUL group (87% of those randomized; 1 patient was excluded for violating the active urinary retention exclusion criterion). Groups were similar at baseline, except for the MSHQ-EjD function score. For procedure recovery, 82% of the PUL group achieved the recovery endpoint by 1 month compared with 53% of the TURP group ($p=.008$). For the study's primary outcome, the proportion of participants who met the original BPH6 primary endpoint was 34.9% for the PUL group, and 8.6% for the TURP group (noninferiority $p<.001$; superiority $p=.006$). The modified BPH6 primary endpoint was met by 52.3% of the PUL group and 20.0% of the TURP group (noninferiority $p<.001$; superiority $p=.005$). Both groups demonstrated improvements over IPSS, IPSS quality of life score, BPH-II score, and Qmax over time, as described in Table 3. There were 60 grade 1 adverse events in 30 (68%) PUL patients and 79 adverse events in 26 (74%) TURP patients. The number of patients experiencing grade 2 and 3 adverse events was similar between groups. Intention-to-treat analyses were not reported.

Gratzke et al (2017) reported on 2-year results from BPH6.³⁵ Two additional patients were excluded from the analysis: 1 TURP patient who discontinued participation; and 1 PUL patient who had a protocol violation. Composite scores for the 2 groups were not reported. Both groups continued to show significant improvements in IPSS score, IPSS quality of life, BPH-II score, and Qmax during the 2 year follow-up, as described in Table 3. Six (14%) PUL patients and 2 (6%) TURP patients had secondary treatment (PUL, intradetrusor botulinum toxin, laser or TURP procedure), showing moderate durability over 2 years.

Tables 4 and 5 display notable limitations identified in each study.

Table 4. Study Relevance Limitations

Study	Population ^a	Intervention ^b	Comparator ^c	Outcomes ^d	Duration of follow-Up ^e
BPH6	3. Unclear history of BPH treatments			4. Primary outcome was not validated	
LIFT	3. Unclear history of BPH treatments		2. Men were washed out of medication		

The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

BPH: benign prostatic hyperplasia.

^a Population key: 1. Intended use population unclear; 2. Study population is unclear; 3. Study population not representative of intended use; 4. Enrolled populations do not reflect relevant diversity; 5. Other.

^b Intervention key: 1. Not clearly defined; 2. Version used unclear; 3. Delivery not similar intensity as comparator; 4. Not the intervention of interest (e.g., proposed as an adjunct but not tested as such); 5. Other.

^c Comparator key: 1. Not clearly defined; 2. Not standard or optimal; 3. Delivery not similar intensity as intervention; 4. Not delivered effectively; 5. Other.

^d Outcomes key: 1. Key health outcomes not addressed; 2. Physiologic measures, not validated surrogates; 3. Incomplete reporting of harms; 4. Not establish and validated measurements; 5. Clinically significant difference not prespecified; 6. Clinically significant difference not supported; 7. Other.

^e Follow-Up key: 1. Not sufficient duration for benefit; 2. Not sufficient duration for harms; 3. Other.

Table 5. Study Design and Conduct Limitations

Study	Allocation ^a	Blinding ^b	Selective Reporting ^c	Data Completeness ^d	Power ^e	Statistical ^f
BPH6		1. Blinding not feasible		6. Only per-protocol analysis presented		
LIFT				1, 2, 5. High losses and/or exclusions in extended follow-up, only LOCF sensitivity analyses provided		3, 4. CI not reported for treatment effects

The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

CI: confidence interval; LOCF: last observation carried forward.

^a Allocation key: 1. Participants not randomly allocated; 2. Allocation not concealed; 3. Allocation concealment unclear; 4. Inadequate control for selection bias.

^b Blinding key: 1. Not blinded to treatment assignment; 2. Not blinded outcome assessment; 3. Outcome assessed by treating physician.

^c Selective Reporting key: 1. Not registered; 2. Evidence of selective reporting; 3. Evidence of selective publication.

^d Data Completeness key: 1. High loss to follow-up or missing data; 2. Inadequate handling of missing data; 3. High number of crossovers; 4. Inadequate handling of crossovers; 5. Inappropriate exclusions; 6. Not intent to treat analysis (per protocol for noninferiority trials).

^e Power key: 1. Power calculations not reported; 2. Power not calculated for primary outcome; 3. Power not based on clinically important difference.

^f Statistical key: 1. Analysis is not appropriate for outcome type: (a) continuous; (b) binary; (c) time to event; 2. Analysis is not appropriate for multiple observations per patient; 3. Confidence intervals and/or p values not reported; 4. Comparative treatment effects not calculated.

LIFT Study

Comparative Data

Roehrborn et al (2013) reported on results of the pivotal LIFT study, an RCT comparing PUL with sham control among 206 individuals ages 50 years and older with lower urinary tract symptoms secondary to BPH.²³ Eligible patients had an American Urological Association Symptom Index (AUASI) score of 13 or greater, Q_{max} of 12 mL/s or less for a 125-mL voided volume, and a prostate volume between 30 and 80 mL. Patients were excluded if there was median lobe obstruction in the prostate, postvoid obstruction of more than 250 mL, or signs of active infection. Patients underwent a washout of BPH medications before enrollment; the washout period was 2 weeks for α -blockers and 3 months for 5 α -reductase inhibitors. Patients were randomized to PUL (n=140) or sham control (n=66) and evaluated at 3 months postprocedure for the trial's primary efficacy endpoint. After that, all patients were unblinded, and sham control patients were permitted to undergo the PUL procedure. Fifty-three control subjects eventually underwent a PUL procedure. The analysis was intention-to-treat. The study met its primary efficacy endpoint, which was that the reduction in AUASI score at 3 months postprocedure had to be at least 25% greater after the PUL than the reduction in AUASI score seen with sham (p=.003). The AUASI score decreased from 24.4 at baseline to 18.5 at 3-month follow-up for sham control patients and from 22.2 at baseline to 11.2 at 3-month follow-up for PUL patients (Table 6). The 3-month change in Q_{max} was 4.28 mL/s for PUL patients and 1.98 mL/s for sham control patients (p=.005). Compared with sham control patients, PUL patients had greater improvements in quality of life scores and BPH-II score (Table 7). Nine serious adverse events in 7 patients were reported in the PUL group, and 1 serious adverse event was reported in the sham group during the first 3 months of follow-up. Limitations in the trial design are summarized in Tables 4 and 5.

McVary et al (2014) reported on sexual function outcomes in a subset of patients from the LIFT study.²⁶ At baseline, 53 (38%) PUL subjects and 23 (53%) sham control subjects were sexually inactive or had severe erectile dysfunction and were censored from the primary sexual function analysis. Scores on the SHIM, MSHQ-EjD function scale, and the MSHQ-EjD bother scale did not differ significantly between groups.

Table 6. Summary of LIFT Initial Trial Results

Study	Change in IPSS	Change in IPSS QOL	Change in Q _{max}	Change in MSHQ-EjD Function	Change in MSHQ-EjD Bother	Any Adverse Events, n (%)	Serious Adverse Events, n (%)
LIFT							
N at 3 months	206	206	182	144	177	206	206
PUL	-11.1 (7.7)	-2.2 (1.8)	4.3 (5.2)	2.2 (2.5)	-0.8 (1.5)	122 (87%)	7 (5%)
Adverse events						268	9
Sham	-5.9 (7.7)	-1.0 (1.5)	2.0 (4.9)	1.7 (2.6)	-0.7 (1.6)	43 (52%)	1 (1.5%)

Study	Change in IPSS	Change in IPSS QOL	Change in Qmax	Change in MSHQ-EjD Function	Change in MSHQ-EjD Bother	Any Adverse Events, n (%)	Serious Adverse Events, n (%)
Adverse events						53	1
TE (p)	NR (.003)	NR (<.001)	NR (.005)	NR (.283)	NR (.60)	NR	NR

Adapted from Roehrborn et al (2013).²³

Values are mean (standard deviation) unless otherwise indicated.

IPSS: International Prostate Symptom Score; MSHQ-EjD: Male Sexual Health Questionnaire for Ejaculatory Dysfunction; NR: not reported; PUL: prostatic urethral lift; Qmax: mean peak urinary flow rate; QOL: quality of life; TE: treatment effect.

Table 7. Summary of Evidence for LIFT Study, Including Participants in the Prostatic Urethral Lift Group

Outcomes	3 Months	1 Year	2 Years	3 Years	5 Years
N	140	129	118	109	87
Death/LTFU	0	2	7	2	18
Protocol deviations	3	0	0	1	0
Retreatment	0	6	4	6	4
Change in IPSS					
n	136	123	103	93	72
Change	-11.14 (7.72)	-10.61 (7.51)	-9.13 (7.62)	-8.83 (7.41)	-35.9%
95% CI	-12.45 to -9.83	-11.95 to -9.27	-10.62 to -7.64	-10.35 to -7.30	-44.4% to -27.3%
p	<.001	<.001	<.001	<.001	<.001
Change in IPSS QOL					
n	136	123	103	93	72
Change	-2.22 (1.78)	-2.31 (1.60)	2.19 (1.72)	-2.25 (1.72)	-50.3
95% CI	-2.52 to -1.92	-2.59 to -2.02	-2.53 to -1.86	-2.60 to -1.89	-58.4% to -42.2%
p	<.001	<.001	<.001	<.001	<.001
Change in Qmax					
n	122	102	86	69	52
Change	4.29 (5.16)	4.03 (4.96)	4.21 (5.09)	3.47 (5.00)	44.3%
95% CI	3.36 to 5.21	3.06 to 5.00	3.12 to 5.30	2.27 to 4.67	29.4% to 59.1%
p	<.001	<.001	<.001	<.001	<.001
Change in SHIM score					
n	91	87	72	66	NR
Change	1.27 (4.65)	0.70 (5.12)	1.06 (4.78)	0.53 (4.41)	NR
95% CI	0.31 to 2.24	-0.39 to 1.79	-0.07 to 2.18	-0.55 to 1.62	NR
p	.005	.299	.046	.338	NR
Change in MSHQ-EjD function score					
n	91	87	72	66	49
Change	2.31 (2.58)	1.56 (2.68)	1.08 (2.51)	0.56 (2.48)	9.3%
95% CI	1.77 to 2.85	0.99 to 2.13	0.49 to 1.67	-0.05 to 1.17	-3.8% to 22.5%
p	<.001	<.001	<.001	.013	.096
Change in MSHQ-EjD bother score					
n	91	87	72	66	49
Change	-1.07 (1.44)	-0.76 (-1.55)	0.63 (1.51)	-0.59 (1.52)	-6.3%
95% CI	-1.37 to -0.77	-1.09 to -0.43	-0.98 to 0.27	-0.96 to -0.22	-31.5% to 18.8%
p	<.001	<.001	<.001	<.001	.019

Adapted from Roehrborn et al (2015)³⁷ for data from 3 months to 3 years and Roehrborn et al (2017)³⁸ for data for 5 years. While not specifically indicated, change values likely represent means and standard deviations.

CI: confidence interval; IPSS: International Prostate Symptom Score; LTFU: lost to follow-up; MSHQ-EjD: Male

Sexual Health Questionnaire for Ejaculatory Dysfunction; NR: not reported; PUL: prostatic urethral lift; Qmax: mean peak urinary flow rate; QOL: quality of life; SHIM: Sexual Health Inventory for Men.

Follow-Up of Sham-Assigned Crossover Participants

Cantwell et al (2014) reported on 12-month outcomes for 53 subjects in the LIFT sham control group who underwent PUL after unblinding at 3 months postprocedure.¹⁶ Crossover (unblinded) patients had a change in IPSS from 23.4 to 12.3 at 3 months postprocedure compared with the change in IPSS from 25.2 to 20.2 at 3 months after the sham procedure. Subjects had greater improvements in BPH-II score in the crossover period (-3.3) than in the sham period (-1.9; $p=.024$) but did not report significant differences in improvement in Qmax. Change in sexual function scores did not differ significantly after the sham procedure compared with after the active procedure.

Rukstalis et al (2016) reported on 24-month outcomes for 42 of the 53 participants in the LIFT sham group who underwent PUL after unblinding.³² During the 24 months, 4 patients were known to have had TURP, and 1 patient required additional PUL implants. The change in IPSS from baseline to 24 months was -9.6 (-35%; 95% CI, not reported; $p<.001$) and there were significant score improvements in Qmax, BPH-II scores, and quality of life. There were no significant changes compared with baseline for SHIM scores; however, MSHQ-EjD scores improved by 41% ($p<.001$).

Follow-Up of Prostatic Urethral Lift-Assigned Participants

Roehrborn et al (2015) reported on 3-year results from patients randomized to PUL in the LIFT study.²⁵ After exclusion of 11 subjects who were lost to follow-up, 36 subjects with missing data, protocol deviations, medication treatment for BPH, or other prostate procedures, and 15 subjects who underwent surgical retreatment for lower urinary tract symptoms (6 with repeat PUL procedures, 9 with TURP or laser vaporization), the 3-year effectiveness analysis included 93 (66%) of the original 140 subjects. For subjects with follow-up data, change in IPSS was -8.83 (95% CI, -10.35 to -7.30; $p<.001$). Significant improvements were also reported for the quality of life score, BPH-II score, and Qmax. Sexual function was unchanged. Implants were removed from 10 participants. No analyses were performed to assess how sensitive the results were to changes in the assumptions about the considerable amount of missing data.

Roehrborn et al (2016) reported on 4-year results from patients randomized to PUL in the LIFT study.³⁷ Of the 140 originally randomized patients, 32 were lost by the 4-year follow-up visit (6 losses were deaths). Of the remaining 108 patients for whom data were available, an additional 29 patients were excluded from analysis for BPH retreatment or protocol deviations. For the 79 (56%) of the 140 subjects included in the analysis, change in IPSS score was -8.8 (precision not given) or -41% (95% CI, -49% to -33%; $p<.001$). Significant improvements (vs baseline) were also reported for scores relating to the quality of life, BPH-II, and Qmax. Authors reported that 14% "of the 140 originally enrolled" participants had surgical retreatment at some point during the 4 years; however, the 4-year follow-up included 79 patients, so the denominator for the 14% is not clear, and estimated retreatment rates are likely underestimated since individuals lost to follow-up could also have received retreatment. Attributes of patients who received retreatment were not analyzed. SHIM scores did not differ statistically from baseline.

Roehrborn et al (2017) reported on 5-year results from patients randomized to PUL in the LIFT study.³⁸ The authors reported 2 analyses. The first was called a per-protocol analysis, which censored patients who had additional BPH procedures, started a BPH medication, or had a protocol deviation. A second analysis was called an intention-to-treat analysis, which used the last observation carried forward to impute values that were censored in the per-protocol analysis. While there were 104 participants with 5-year data, only 72 patients (approximately 50% of those randomized) were included in the per-protocol analysis after exclusion for protocol violations, additional BPH procedures, or treatment with BPH medication. In the intention-to-treat analysis, change in IPSS was -7.85 at 5 years (-35%; 95% CI, -41% to -29%; $p<.001$). In the per-protocol analysis, change in IPSS was -7.56 at 5 years (-35.9%; 95% CI, -44% to -27%). Significant improvements, compared with baseline,

continued to be reported for scores associated with quality of life, Qmax, and BPH-II. Of the limited number of patients that remained in the analysis, 13.6% had surgical reintervention by 5 years.

Section Summary: Randomized Controlled Trials

The BPH6 study demonstrated that PUL is noninferior to TURP when assessed by a composite score, which reflects concurrent improvements in validated scales of symptoms, safety, and sexual function. These findings are reflected in the analysis of the individual aspects of the composite score. Prostatic urethral lift demonstrates measurable improvements in urinary symptoms to 2 years and is superior to TURP in preserving ejaculatory function. These findings were confirmed in the LIFT study, which compared PUL with a sham treatment. Prior to crossover at 3 months, patients were found to have greater improvement in urinary symptoms relative to patients receiving sham treatment and preserved sexual function. After 3 months, 80% of patients who had received a sham treatment chose to have the PUL procedure. Patients treated with PUL had improvement of urinary symptoms with preservation of sexual function, consistent with the BPH6 study. These findings were preserved in a subset of patients over 3 to 5 years; a high number of patients were either excluded or lost to follow-up during this time. The BPH6 and LIFT RCTs excluded men with median lobe obstruction.

Nonrandomized Studies

The approved indications for PUL have expanded since the original approval to include men with median lobe obstruction and those with prostate volume between 80cc and 100cc. Neither of these expansions have supporting RCTs.

Median Lobe Obstruction

Several noncomparative studies were published including men without median lobe obstruction. These studies were previously enumerated in the description of the systematic reviews and are shown in Appendix Table 3. Since RCTs with long-term follow-up exist for this population, these noncomparative studies will not be discussed in further detail.

Rukstalis et al (2019) reported results of the prospective MedLift study, the study used to support the expansion of the FDA clearance for PUL to include obstructive median lobes.³⁹ MedLift was a single-arm study enrolling 45 men with eligibility criteria identical to LIFT except requiring obstructive median lobes. Results in the MedLift cohort were compared to the LIFT historical cohort. Characteristics are shown in Table 8 and results are shown in Table 9. One patient required surgical retreatment and no implants were removed over the 12 months of follow-up.

Eure et al (2023) published results from a real-world retrospective database analysis (N=2078) of consecutive PUL patients filtered to match MedLift criteria with results stratified by obstructive median lobe (n=180) or lateral lobe (n=1271) morphology.⁴⁰ Characteristics are shown in Table 8 and results through 12 months are shown in Table 9. Additionally, no statistically significant differences were noted with comparison of the MedLift cohort versus TURP control subjects in the BPH6 RCT at 12 months for IPSS, QoL, and post-void residual outcomes (not shown below).

Table 8. Summary of Characteristics of Key Nonrandomized Studies

Study	Country	Sites	Participants	Treatment Delivery	Follow-Up
Rukstalis (2019) ³⁹	US	9	Men ages 50+ with IPSS>13, Qmax ≤12 mL/s, 30 to 80 cc intraurethral prostatic volume, and OML ^a (n=45)	UroLift PUL procedure with median lobe deployment	12 months
Eure (2023) ⁴⁰	US	22	Patients not in retention at baseline, IPSS ≥8 and no prior BPH treatment filtered to match MedLift (n= 180 with OML; n=1279 with LL)	UroLift PUL procedure with median lobe or lateral lobe deployment	12 months

BPH: benign prostatic hyperplasia; IPSS: International Prostate Symptom Score; LL: lateral lobe; OML: obstructive median lobe; PUL: prostatic urethral lift; Qmax: mean peak urinary flow rate.

^aOML was defined as excessive posterior tissue that precludes a normal lateral lobe procedure.

Table 9. Summary Results of Key Nonrandomized Studies

Study	IPSS	IPSS QOL	Qmax	SHIM
Rukstalis (2019)³⁹	At 12 m	At 12 m	At 12 m	At 12 m
OML (n)	44	44	37	38
Change from baseline, mean (SD); p-value	-13.5 (7.7); p<.001	-3.0 (1.5); p<.001	6.4 (7.4); p<.001	1.2 (4.3); p=.04
Eure (2023)⁴⁰	At 12 m	At 12 m	At 12 m	At 12 m
	OML: 30	OML: 25	OML: 1	
	LL: 241	LL: 155	LL: 42	
OML: Change from baseline, mean (SD)	-11.6 (9.2)	-2.1 (2.0)	7.1 (NR)	NR
LL: Change from baseline, mean (SD)	-8.5 (7.5)	-1.6 (1.6)	3.1 (6.7)	NR
Change versus MedLift for OML and LL; p-value	.56; <.01	.06; <.01	.99; 1	NR

IPSS: International Prostate Symptom Score; LL: lateral lobe; NR: not reported; OML: obstructive median lobe; Qmax: mean peak urinary flow rate; QOL: quality of life; SHIM: Sexual Health Inventory for Men; SD: standard deviation.

Tables 10 and 11 display notable limitations identified in each study.

Table 10. Study Relevance Limitations

Study	Population ^a	Intervention ^b	Comparator ^c	Outcomes ^d	Duration of follow-Up ^e
Rukstalis (2019)³⁹	3. Unclear history of BPH treatments		2: No concurrent comparator	3: Reporting of adverse events was qualitative; rates not reported	1, 2: Only 12 m of follow-up reported
Eure (2023)⁴⁰			2: No concurrent comparator		1, 2: Only 12 m of follow-up reported

The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

BPH: benign prostatic hypertrophy.

^a Population key: 1. Intended use population unclear; 2. Study population is unclear; 3. Study population not representative of intended use; 4. Enrolled populations do not reflect relevant diversity; 5. Other.

^b Intervention key: 1. Not clearly defined; 2. Version used unclear; 3. Delivery not similar intensity as comparator; 4. Not the intervention of interest (e.g., proposed as an adjunct but not tested as such); 5. Other.

^c Comparator key: 1. Not clearly defined; 2. Not standard or optimal; 3. Delivery not similar intensity as intervention; 4. Not delivered effectively; 5. Other.

^d Outcomes key: 1. Key health outcomes not addressed; 2. Physiologic measures, not validated surrogates; 3. Incomplete reporting of harms; 4. Not establish and validated measurements; 5. Clinically significant difference not prespecified; 6. Clinically significant difference not supported; 7. Other.

^e Follow-Up key: 1. Not sufficient duration for benefit; 2. Not sufficient duration for harms; 3. Other.

Table 11. Study Design and Conduct Limitations

Study	Allocation ^a	Blinding ^b	Selective Reporting ^c	Data Completeness ^d	Power ^e	Statistical ^f
Rukstalis (2019)³⁹	1,2. Not randomized	1,2. No blinding		1. >15% missing data for Qmax and SHIM		3. CIs not reported
Eure (2023)⁴⁰	1,2: Not randomized; retrospective design	1,2. No blinding		1. >80% missing data for IPSS; incomplete baseline data across other outcomes		3. CIs not reported

The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

CI: confidence interval; IPSS: International Prostate Symptom Score; Qmax: mean peak urinary flow rate; SHIM:

Sexual Health Inventory for Men.

^a Allocation key: 1. Participants not randomly allocated; 2. Allocation not concealed; 3. Allocation concealment unclear; 4. Inadequate control for selection bias.

^b Blinding key: 1. Not blinded to treatment assignment; 2. Not blinded outcome assessment; 3. Outcome assessed by treating physician.

^c Selective Reporting key: 1. Not registered; 2. Evidence of selective reporting; 3. Evidence of selective publication.

^d Data Completeness key: 1. High loss to follow-up or missing data; 2. Inadequate handling of missing data; 3. High number of crossovers; 4. Inadequate handling of crossovers; 5. Inappropriate exclusions; 6. Not intent to treat analysis (per protocol for noninferiority trials).

^e Power key: 1. Power calculations not reported; 2. Power not calculated for primary outcome; 3. Power not based on clinically important difference.

^f Statistical key: 1. Analysis is not appropriate for outcome type: (a) continuous; (b) binary; (c) time to event; 2. Analysis is not appropriate for multiple observations per patient; 3. Confidence intervals and/or p values not reported; 4. Comparative treatment effects not calculated.

Prostate Volume Greater Than 80 mL

Sievert et al (2019) reported results of a noncomparative study that included 5 men with prostate volume greater than 80 mL.³³ Results were not presented stratified by prostate volume.

Shah et al (2018) reported a retrospective review of 74 patients at a single institution that had undergone PUL between 2014 and 2015.⁴¹ Twenty-three of the patients had prostates larger than 80 g (median, 112 g; range, 81 to 254 g); 5 of the men with larger prostates had obstructive median lobe. Overall, median follow-up time between the date of PUL procedure and the last reported symptom rating during follow-up was 144 days; follow-up was not reported separately for the men with a larger prostate volume. In the men with larger prostate volume, the median pre-operative AUA symptom score was 12. Twenty of the 23 men had post-operative AUA symptom scores with a median score of 3 (median improvement = 9; $p < .001$). Three (13%) of the men with a larger prostate volume had a repeat outlet procedure.

Eure et al (2019)⁴² included 38 men with a prostate volume >80 mL. Although the authors reported that "no significant differences in symptom response emerged based on prostate volume," results were not presented stratified by volume.

Bozkurt et al (2016)²⁹, Woo et al (2012)²⁰, and Chin et al (2012)¹⁹ included men with a prostate volume greater than 80 mL, but had a mean volume in the 40 to 60 mL range. It is unclear how many patients had a volume greater than 80 mL.

Given the limited amount of published data on outcomes for men with a prostate volume greater than 80 mL and limited follow-up, the risks and benefits cannot be evaluated.

Section Summary: Noncomparative Studies

One single-arm study (N=45) including men with obstructive median lobes has been conducted and was used to support the FDA expansion of the PUL indication. Symptom scores and quality of life appeared to improve by statistically and clinically significant amounts and were similar in magnitude to improvements reported in the original LIFT study. Rates of adverse events were not reported. Design and conduct limitations preclude interpretation.

Noncomparative studies have included a small number of men with a larger prostate volume, but have generally not reported results stratified by volume. One study presented data for 20 men with less than 6 months of follow-up.

Repeat Prostatic Urethral Lift

Clinical Context and Therapy Purpose

The purpose of repeat PUL in individuals with lower urinary tract obstruction symptoms due to BPH who have had a prior PUL is to provide a treatment option that is an alternative to or an improvement on existing therapies such as medical management or TURP.

The following PICO was used to select literature to inform this review.

Populations

The relevant population of interest is men who are experiencing lower urinary tract symptoms without a history of an alternative non-BPH etiology and who have undergone a prior PUL.

Interventions

The therapy being considered is repeat PUL. The PUL procedure involves the placement of 1 or more implants in lobes of the prostate using a transurethral delivery device. The implant device is designed to retract the prostate to allow expansion of the prostatic urethra. The implants are retained in the prostate to maintain an expanded urethral lumen. One device, the NeoTract UroLift System, has been cleared for marketing by the FDA (see Regulatory Status section). The device has 2 main components: the delivery device and the implant. Each delivery device comes preloaded with a UroLift implant.

Comparators

The following practices are currently being used to treat BPH in this setting. TURP is generally considered the reference standard for comparisons of BPH procedures. Several minimally invasive prostate ablation procedures have also been developed, including transurethral microwave thermotherapy, transurethral needle ablation of the prostate, urethromicroablation phototherapy, and photoselective vaporization of the prostate.

Outcomes

A number of health status measures are used to evaluate symptoms relevant to BPH and adverse events of treatment for BPH, including urinary symptoms, urinary dysfunction measured by Qmax, ejaculatory dysfunction, overall sexual health, and overall quality of life. Qmax is measured by uroflowmetry; low rates are associated with more voiding dysfunction and rates <10 mL/sec are considered obstructed.

Outcomes data demonstrating durability to at least 2 years is preferred.

Some validated patient-reported scales are shown in Table 1.

Of note, the prostate volume does not have a direct correlation with the severity of urinary symptoms.⁸

Study Selection Criteria

Methodologically credible studies were selected using the following principles:

- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
- To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- Studies with duplicative or overlapping populations were excluded.

Review of Evidence

Clinical data are limited regarding PUL reintervention/retreatment and investigators continue to emphasize the need for consensus definitions of these outcomes in future studies.^{43,44} The majority of data concerning lower urinary tract symptoms/BPH define retreatment, reintervention, or treatment failure in an individualized manner with considerable variation across trials. Studies assessing the need for additional surgical procedures (for implant misplacement, malfunction, encrustation, infection, or lack of continued efficacy), failure to remove or wean off BPH medications, or the initiation of new BPH medications after the initial intervention have all been evaluated.⁴⁵ There is no consensus definition of retreatment/reintervention in this setting or regulatory guidance. Additionally, data on factors that may identify patients at high risk for retreatment/reintervention such as measures of patient symptoms, prostate specific antigen levels, or prostatic volumes are often absent in the reporting.

Retreatment rates in the long-term follow-up of the LIFT study were reviewed in the Follow-Up of PUL-Assigned Participants section of this evidence review. Of the limited number of patients that remained in the analysis, 13.6% had a surgical reintervention by 5 years.³⁸

Systematic Reviews

Miller et al (2020) reported results of a systematic review and meta-analysis on the surgical reintervention rate of PUL utilizing a life table method.⁴⁶ Randomized or nonrandomized controlled studies and prospective and retrospective observational studies published through January 2020 were eligible for inclusion. Eleven studies (9 observational, 2 RCTs) were included with a total of 2016 patients. There were 153 surgical reinterventions performed (TURP, 51.0%; repeat PUL, 32.7%, device explant, 19.6%). Per the authors, the annual rate of surgical reintervention was 6.0% per year (95% CI, 3.0% to 8.9%): 4.3% per year in studies with ≤ 1 year mean follow-up, 10.7% per year in studies with >1 year to 3 years mean follow-up, and 5.8% per year in 1 study with >3 years mean follow-up. No information was provided on the success of the reinterventions.

Observational Studies

Gaffney et al (2021) performed a retrospective healthcare system database analysis of inpatient and ambulatory endoscopic procedures for BPH, identifying 175,150 men treated between 2000 and 2018.⁴⁷ More than half were treated with TURP, compared to 27% with prostate photovaporization and 10% with PUL. Readmission rates at 30 days were 2.2% for TURP, 2.1% for prostate photovaporization, and 1.2% for PUL (odds ratio [OR], 0.58; $p < .01$). Ninety-day readmission rates were 5.7% for TURP, 6.0% for prostate photovaporization, and 2.9% for PUL (OR, 0.55; $p < .01$). However, patients treated with PUL were almost twice as likely to be retreated at 2-year follow-up compared to those receiving TURP (OR, 1.78; $p < .01$). Retreatment rates at 2-years were 5.2% for PUL, 3.2% for prostate photovaporization, and 2.9% for TURP.

Page et al (2021) identified a retrospective observational cohort (N=2942 UroLift procedures from 2942 patients) and reported on care setting real world experience outcomes of PUL procedures conducted in hospitals across England.⁴⁸ During follow-up, 206 patients required retreatment with 57 patients (4.2%) requiring further UroLift intervention and 158 patients (5.4%) requiring endoscopic interventions. Subsequent UroLift treatment at 1 and 2 years was 1.5% (95% CI, 1.0 to 2.0) and 3% (95% CI, 2.1 to 3.8), respectively, while subsequent endoscopic treatment (no UroLift) was 3.9% (95% CI, 3.0 to 4.7) and 9.5% (95% CI, 7.9 to 10.1). The overall retreatment rate at 1 and 2 years was 5.2% (95% CI, 4.2 to 6.1) and 11.9% (95% CI, 10.1 to 13.6), respectively.

Eure et al (2019) completed a retrospective chart review and analysis of 1413 patients who underwent a PUL procedure in North America and Australia.⁴² In this study, 72 patients underwent either a PUL retreatment (n=39) or an alternative surgical intervention (17 laser procedures; 16 TURPs), 11 of which included implant removal.

Section Summary: Repeat Prostatic Urethral Lift

Clinical data on repeat PUL are limited and there is no consensus on definitions of clinically meaningful types of retreatment or reintervention and their associated outcomes. The 5 year surgical reintervention rate in the LIFT study was reported as 13.6% while a meta-analysis calculated a surgical reintervention rate following PUL at 6% per year. One analysis of clinical care setting real world experience reported the overall retreatment rate at 1 and 2 years to be 5.2% (95% CI, 4.2 to 6.1) and 11.9% (95% CI, 10.1 to 13.6), respectively, following an initial PUL. A retrospective healthcare system database analysis of endoscopic procedures for BPH (N=175,150) found that patients treated with PUL were almost twice as likely to be retreated at 2-year follow-up compared to those receiving TURP (OR, 1.78; p<.01).

Supplemental Information

The purpose of the following information is to provide reference material. Inclusion does not imply endorsement or alignment with the evidence review conclusions.

Clinical Input From Physician Specialty Societies and Academic Medical Centers

While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process, through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.

2017

Clinical input was sought to help determine whether the use of PUL for individuals with lower urinary tract obstruction symptoms due to BPH who do not have sufficient response to medical therapy or are experiencing significant side effects with medical therapy would provide a clinically meaningful improvement in net health outcome and whether the use is consistent with generally accepted medical practice. In response to requests, while this policy was under review in 2017, clinical input on the use of a prostatic urethral lift for 3 indications were received from 4 respondents, including 2 physician-level responses identified through a specialty society and 2 physician-level responses identified through an academic medical center. Input consistently supported that the use of PUL for individuals with moderate-to-severe lower urinary tract obstruction symptoms due to BPH provides a clinically meaningful improvement in net health outcome and indicates this use is consistent with generally accepted medical practice. See Appendices 1 and 2 for details of the clinical input.

Practice Guidelines and Position Statements

Guidelines or position statements will be considered for inclusion in 'Supplemental Information' if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

National Institute for Health and Care Excellence

In 2014, the National Institute for Health and Care Excellence published guidance on urethral lift implants to treat lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH).⁴⁹ The guidance stated:

"Current evidence on the efficacy and safety of insertion of prostatic urethral lift implants to treat lower urinary tract symptoms secondary to benign prostatic hyperplasia is adequate to support the use of this procedure."

In 2021, the National Institute for Health and Care Excellence published updated guidance on the use of UroLift for treating LUTS of BPH.⁵⁰ The guidance stated: "the UroLift system relieves lower urinary tract symptoms, avoids risk to sexual function, and improves quality of life" and "the UroLift system should be considered as an alternative to transurethral resection of the prostate (TURP) and

holmium laser enucleation of the prostate (HoLEP). It can be done as a day-case or outpatient procedure for people aged 50 and older with a prostate volume between 30 and 80 mL."

American Urological Association

In 2018, the American Urological Association published guidelines on the surgical management of LUTS attributed to BPH; the 2018 guidelines were most recently amended in 2021.⁷ The guidelines made the following recommendations and statements regarding prostatic urethral lift (PUL).

- "PUL may be offered as an option for patients with LUTS [lower urinary tract symptoms] /BPH [benign prostatic hyperplasia] provided prostate volume 30-80cc and verified absence of an obstructive middle lobe "
 - "Moderate Recommendation; Evidence Level: Grade C indicating "Benefits > Risks/Burdens (or vice versa); Net benefit (or net harm) appears moderate. Applies to most patients in most circumstances but better evidence is likely to change confidence"
- "PUL may be offered as a treatment option to eligible patients who desire preservation of erectile and ejaculatory function."
 - "Conditional Recommendation; Evidence Level: Grade C indicating "Risks/Burdens unclear; Alternative strategies may be equally reasonable. Better evidence likely to change confidence"
- "Clinicians should inform patients of the possibility of treatment failure and the need for additional or secondary treatments when considering surgical and minimally-invasive treatments for LUTS/BPH."
- "Surgery is recommended for patients who have renal insufficiency secondary to BPH, refractory urinary retention secondary to BPH, recurrent urinary tract infections (UTIs), recurrent bladder stones or gross hematuria due to BPH, and/or with LUTS/BPH refractory to or unwilling to use other therapies."

U.S. Preventive Services Task Force Recommendations

Not applicable.

Medicare National Coverage

There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

Ongoing and Unpublished Clinical Trials

Some currently unpublished trials that might influence this review are listed in Table 12.

Table 12. Summary of Key Trials

NCT No.	Trial Name	Planned Enrollment	Completion Date
<i>Ongoing</i>			
NCT04987892 ^a	Investigating Medication vs. Prostatic Urethral Lift: Assessment and Comparison of Therapies for Benign Prostatic Hyperplasia	250	Oct 2025 (recruiting)
NCT05784558 ^a	RELIEF Study: Real-world Evaluation of LUTS Interventions and Patient Experience During Follow-up	2500	Dec 2030 (not yet recruiting)

NCT: national clinical trial.

^a Denotes industry-sponsored or cosponsored trial.

Appendix 1 and 2

Appendix 1: Clinical Input

Appendix Table 1. Respondent Profile

Physician					
No.	Name	Degree	Institutional Affiliation	Clinical Specialty	Board Certification and Fellowship Training
<i>Identified by American Urological Association</i>					
1	Anonymous	MD	St. Joseph Hospital	Urology	American Board of Urology
2	John C. Lin	MD	Sunrise Urology	Urology	American Board of Urology
<i>Identified by University of California San Francisco Medical Center</i>					
3	Anonymous	MD	University of California San Francisco Medical Center	Urology	American Board of Urology, Endourology and Urologic Oncology
4	Anonymous	MD	University of California San Francisco Medical Center	Urology	American Board of Urology Eligible, Fellowship trained in male reconstruction

Clinical input provided by the specialty society at an aggregate level is attributed to the specialty society. Clinical input provided by a physician member designated by a specialty society or health system is attributed to the individual physician and is not a statement from the specialty society or health system. Specialty society and physician respondents participating in the Evidence Street® clinical input process provide review, input, and feedback on topics being evaluated by Evidence Street. However, participation in the clinical input process by a specialty society and/or physician member designated by a specialty society or health system does not imply an endorsement or explicit agreement with the Evidence Opinion published by BCBSA or any Blue Plan.

Appendix 1 Table 2. Respondent Conflict of Interest Disclosure

No. 1. Research support related to the topic where clinical input is being sought		2. Positions, paid or unpaid, related to the topic where clinical input is being sought		3. Reportable, more than \$1000, healthcare-related assets or sources of income for myself, my spouse, or my dependent children related to the topic where clinical input is being sought		4. Reportable, more than \$350, gifts or travel reimbursements for myself, my spouse, or my dependent children related to the topic where clinical input is being sought	
Yes/No	Explanation	Yes/No	Explanation	Yes/No	Explanation	Yes/No	Explanation
1	No	Yes	Teach UroLift procedure	Yes	Teach UroLift procedure	No	
2	No	Yes	I currently offer the Prostatic Urethral Lift as part of the standard of care for BPH for essentially all patients but my patients covered by the BCBS plan in my state. I have been designated as a Center of Excellence in this care.	No		No	
3	No	No		No		No	
4	No	No		No		No	

Individual physician respondents answered at individual level. Specialty Society respondents provided aggregate information that may be relevant to the group of clinicians who provided input to the Society-level

response.

BPH: benign prostatic hyperplasia.

Appendix 2: Clinical Input Responses

CI-Objective:

Benign prostatic hyperplasia is a common condition in older men that can lead to increased urinary frequency, an urgency to urinate, a hesitancy to urinate, nocturia, and a weak stream when urinating. The prostatic urethral lift (PUL) procedure involves the insertion of 1 or more permanent implants into the prostate, which retracts prostatic tissue and maintains an expanded urethral lumen.

Clinical input was sought to help determine whether the use of PUL for individuals with moderate-to-severe lower urinary tract obstruction symptoms (due to benign prostatic hyperplasia) would provide a meaningful clinical benefit, defined as improved net health outcome, and whether this use is consistent with generally accepted medical practice.

Responses

1. Based on the evidence and your clinical experience, describe for each clinical indication listed below the clinical context that may offer clinical benefit.
 - a. Provide supporting rationale and explanation of objective condition characteristics (e.g., patient selection criteria such as American Urological Association Symptom Index or the International Prostate Symptom Score, prostate size, or patient age) and any management criteria (i.e., regarding prior application of standard diagnostic or therapeutic options) for clinical use.
 - b. Include any relevant references to support your clinical input.

No.	Indications	Rationale
1	PUL for individuals with moderate-to-severe lower urinary tract obstruction symptoms (due to benign prostatic hyperplasia)	Used for management of benign prostatic hyperplasia (BPH)
	PUL for individuals with moderate-to-severe lower urinary tract obstruction symptoms (due to benign prostatic hyperplasia) and failed medical management	Yes
	PUL for individuals with moderate-to-severe lower urinary tract obstruction symptoms (due to benign prostatic hyperplasia) and not surgical candidate	Yes
2	PUL for individuals with moderate-to-severe lower urinary tract obstruction symptoms (due to benign prostatic hyperplasia)	PUL should be offered under similar criteria to other BPH treatment options. The AUA BPH guidelines state that moderate to severe symptoms are AUASI>7 and designate candidacy for all options. While medical therapy should be offered, all treatment options should be discussed and patients should select the appropriate treatment often relying on how bothered they are by symptoms or current treatment side effects. I routinely treat these patients with PUL with excellent results that reflect those published in numerous studies.
	PUL for individuals with moderate-to-severe lower urinary tract obstruction symptoms (due to benign prostatic hyperplasia) and	In general, patients select PUL after trying medical therapy, but holding this as a criterion for treatment is not recommended by AUA BPH guidelines, nor is it standard practice. There are many reasons certain men may wish to avoid medication or increasing their polypharmacy, common in this demographic. If a man wishes to continue medical therapy, he is usually returned to the care of his PCP until such time as he wishes to be more definitively treated. This makes

No.	Indications	Rationale
	failed medical management	sense for my practice and is undoubtedly more efficient quality care within insurance systems. If a man cannot tolerate medical therapy or is responding poorly to medical therapy, PUL is the obvious next line treatment option. It is the least invasive option that offers the most rapid result, the only option to not induce sexual dysfunction, and an option that has been shown to be at least as durable and arguably more durable than heat ablation treatments currently covered by the BCBS plan in my state.
	PUL for individuals with moderate-to-severe lower urinary tract obstruction symptoms (due to benign prostatic hyperplasia) and not surgical candidate	This is an important subset patient population that is well-served by PUL, but is already indicated by Indication #1 discussed above. By no means, however, should PUL indication be limited to this very sick population, as the majority of data published support PUL safety and effectiveness in healthier populations of #1. I deliver PUL in my office with minimal anesthesia required, a critical risk for these patients. As bleeding and bladder irrigation are minimized in PUL when compared to other BPH procedures, the risk of post-op fluid shifts, transfusion, and readmissions is greatly minimized. There are very few of these patients included in the broad bibliography of clinical studies, but my personal experience has been positive.
3	PUL for individuals with moderate-to-severe lower urinary tract obstruction symptoms (due to benign prostatic hyperplasia)	PUL is reasonable if patients are unable to tolerate initial medical therapy. The benefit of PUL compared to TURP is less invasive procedure with fewer potential complications and side effects. However, I believe that medical therapy would still be first-line intervention.
	PUL for individuals with moderate-to-severe lower urinary tract obstruction symptoms (due to benign prostatic hyperplasia) and failed medical management	After failure of medical management, I think offering PUL and TURP would be equivalent. First, the efficacy of PUL appears to be clinically meaningful with fewer attendant risks. Moreover, the durability appears to be comparable to TURP. PUL may be more appropriate for younger patients where concern over erectile dysfunction (ED) and ejaculatory dysfunction may be more important. In addition, the prostate anatomy may impact selection - with a normal bladder neck and primarily lateral lobe obstruction better candidates for PUL, as well as not massively enlarged prostates.
	PUL for individuals with moderate-to-severe lower urinary tract obstruction symptoms (due to benign prostatic hyperplasia) and not surgical candidate	This is the most likely clinical scenario for PUL, where the risks of TURP outweigh the benefits. We have many patients for whom TURP and the associated anesthesia pose significant risks. Thus, PUL may be the best approach with the ability to perform the procedure under anesthesia, and no risks of bleeding nor electrolyte and fluid abnormalities.
4	PUL for individuals with moderate-to-severe lower urinary tract obstruction symptoms (due to benign prostatic hyperplasia)	Short-term data show symptom improvement based on IPSS symptom score compared with other surgical treatment such as TURP.
	PUL for individuals with moderate-to-severe lower urinary tract obstruction symptoms (due to benign prostatic hyperplasia) and failed medical management	For patients who have failed medical management or cannot tolerate medical management, PUL offers a good alternative to TURP given that in short-term data it has shown improvement of symptom scores, and has low risk of complications
	PUL for individuals with moderate-to-severe lower urinary tract obstruction symptoms (due to benign prostatic hyperplasia) and not surgical candidate	PUL can be performed under minimal or even no sedation, providing a good alternative for patients who cannot tolerate anesthesia for TURP.

2. Based on the evidence and your clinical experience for the indications described in Question 1:
 - a. Respond Yes or No for each clinical indication whether the intervention would be expected to provide a meaningful clinical benefit in the net health outcome.

- b. Use the 1 to 5 scale outlined below to indicate your level of confidence that there is adequate evidence that supports your conclusions.

No.	Indications	Yes/No	Low Confidence		Intermediate Confidence		High Confidence	
			1	2	3	4	5	
1	PUL for individuals with moderate-to-severe lower urinary tract obstruction symptoms (due to benign prostatic hyperplasia)	Yes						X
	PUL for individuals with moderate-to-severe lower urinary tract obstruction symptoms (due to benign prostatic hyperplasia) and failed medical management	Yes						X
	PUL for individuals with moderate-to-severe lower urinary tract obstruction symptoms (due to benign prostatic hyperplasia) and not surgical candidate	Yes						X
2	PUL for individuals with moderate-to-severe lower urinary tract obstruction symptoms (due to benign prostatic hyperplasia)	Yes						X
	PUL for individuals with moderate-to-severe lower urinary tract obstruction symptoms (due to benign prostatic hyperplasia) and failed medical management	Yes						X
	PUL for individuals with moderate-to-severe lower urinary tract obstruction symptoms (due to benign prostatic hyperplasia) and not surgical candidate	Yes			X			
3	PUL for individuals with moderate-to-severe lower urinary tract obstruction symptoms (due to benign prostatic hyperplasia)	Yes			X			
	PUL for individuals with moderate-to-severe lower urinary tract obstruction symptoms (due to benign prostatic hyperplasia) and failed medical management	Yes						X
	PUL for individuals with moderate-to-severe lower urinary tract obstruction symptoms (due to benign prostatic hyperplasia) and not surgical candidate	Yes						X
4	PUL for individuals with moderate-to-severe lower urinary tract obstruction symptoms (due to benign prostatic hyperplasia)	Yes						X
	PUL for individuals with moderate-to-severe lower urinary tract obstruction symptoms (due to benign prostatic hyperplasia) and failed medical management	Yes			X			
	PUL for individuals with moderate-to-severe lower urinary tract obstruction symptoms (due to benign prostatic hyperplasia) and not surgical candidate	Yes						X

3. Based on the evidence and your clinical experience for the indications described in Question 1:
- Respond Yes or No for each indication whether this intervention is consistent with generally accepted medical practice.
 - Use the 1 to 5 scale outlined below to indicate your level of confidence in your conclusions.

No.	Indications	Yes/No	Low Confidence		Intermediate Confidence		High Confidence	
			1	2	3	4	5	
1	PUL for individuals with moderate-to-severe lower urinary tract obstruction symptoms (due to benign prostatic hyperplasia)	Yes						X
	PUL for individuals with moderate-to-severe lower urinary tract obstruction symptoms (due to benign prostatic hyperplasia) and failed medical management	Yes						X
	PUL for individuals with moderate-to-severe lower urinary tract obstruction symptoms (due to benign prostatic hyperplasia) and not surgical candidate	Yes						X
2	PUL for individuals with moderate-to-severe lower urinary tract obstruction symptoms (due to benign prostatic hyperplasia)	Yes						X
	PUL for individuals with moderate-to-severe lower urinary tract obstruction symptoms (due to benign prostatic hyperplasia) and failed medical management	Yes						X
	PUL for individuals with moderate-to-severe lower urinary tract obstruction symptoms (due to benign prostatic hyperplasia) and not surgical candidate	Yes			X			
3	PUL for individuals with moderate-to-severe lower urinary tract obstruction symptoms (due to benign prostatic hyperplasia)	No			X			
	PUL for individuals with moderate-to-severe lower urinary tract obstruction symptoms (due to benign prostatic hyperplasia) and failed medical management	Yes						X
	PUL for individuals with moderate-to-severe lower urinary tract obstruction symptoms (due to benign prostatic hyperplasia) and not surgical candidate	Yes						X
4	PUL for individuals with moderate-to-severe lower urinary tract obstruction symptoms (due to benign prostatic hyperplasia)	Yes			X			
	PUL for individuals with moderate to severe lower urinary tract obstruction symptoms (due to benign prostatic hyperplasia) and failed medical management	Yes			X			
	PUL for individuals with moderate-to-severe lower urinary tract obstruction symptoms (due to benign prostatic hyperplasia) and not surgical candidate	Yes			X			

4. Additional comments and/or any citations supporting your clinical input on this topic.

No. Additional Comments

- I have used UroLift for failed medical therapies and failed microwave treatments. Good success in patients with short term urinary retention. Ninety percent of such patients are catheter free at 4 weeks. Done most often in office with oral sedation.
- PUL is an important and medically necessary part of my BPH practice for Medicare, United Healthcare, Cigna, Aetna and several out-of-state Blue Cross plans. These insurers have correctly determined that it is advantageous and necessary to offer their beneficiaries access to receiving treatment for BPH without causing potentially permanent damage to their sexual function. They appreciate that outpatient or, in my

No. Additional Comments

case, office treatment is more efficient, less costly, and provides better quality of care for their beneficiaries. TURP and laser treatments, the primary BPH procedures performed, are constantly in the top 20 surgeries for highest readmission rates, yet PUL has nearly none. The BCBSA draft analysis has inaccuracies that I will address below. Most importantly, BCBSA draft analysis is conducted in a vacuum without references that are available for other BPH services. The clinical evidence supporting PUL is superior in quality and at least similar in quantity to most BCBSA recommended BPH treatment services. While there can always be criticisms of scientific studies, the key point is to determine whether the evidence is sufficient to understand the treatment effect on net health outcomes. The answer to this is "yes" when it comes to PUL. PUL studies show irrefutably and consistently that symptoms, quality of life, and urinary flow improve. PUL is done with clearly lower morbidity than other currently recommended BPH procedures. Importantly, it has been consistently demonstrated to be the only treatment option that protects a patient from losing sexual function. There is clear dissidence between the BCBSA analysis of clinical evidence and the draft conclusion that the evidence is in any way insufficient to determine utility and effect on net health outcomes. One may ask in this field, "what is net health outcome?" It is not just an AUA Symptom Index improvement, nor an improvement in urinary flow; it is both of these without causing unnecessary harm to the patient (e.g. sexual dysfunction; urinary incontinence; extended recovery; readmissions for bleeding, clot retention, and ER visits due to catheterization, etc.). PUL offers this complete package as well as, or better than, any BPH service that BCBSA currently recommends.

3 Nothing Listed

4 In short- to medium-term studies, PUL shows improvement in patient symptom score. This provides a meaningful alternative to medical management or transurethral resection/ablation of the prostate. The benefit of PUL is that it can be done under minimal sedation, which provides a possibility of a procedure to benefit patients who have failed or cannot tolerate medical therapy but who are at high risk for general anesthesia. In addition, PUL can be performed safely for patients on anticoagulation, and this provides a significant benefit compared to TURP given that the risk of bleeding from TURP on anticoagulation is high, and this provides an alternative with a lower complication risk in that regard. Finally, the PUL sutures can be later removed during TURP, so this therapy does not preclude a TURP in the future if necessary for improved symptom control.

5. Is there any evidence missing from the attached draft review of evidence that demonstrates clinical benefit?

No. Yes/No Citations of Missing Evidence

1 No

2 Yes I would like to offer my corrections/edits of the analysis:

1. Sexual Function analyses: there appears to be a misunderstanding of the treatment goal of this therapy. PUL is not designed to improve sexual function; it is the only BPH treatment to ever show that it does not cause sexual dysfunction. Mean MSHQ scores stay stable or improve, which is good, but the most important sexual function data are that there have been no (0) accounts of induced sexual dysfunction with PUL, compared to 65% to 90% for standard surgery and 8%-16% for heat ablation. This is a very important consideration from a defensive medicine perspective. By not allowing access to PUL, a provider and/or insurer is causing a patient to undergo an unnecessary risk of losing part or all of his sexual function and lifestyle. No other option can preserve sexual function as reliably as PUL.
2. BPH6 ejaculatory dysfunction (EjD) endpoint was not a mean score, but instead how many men completely lost the ability to ejaculate: 40% TURP vs 0% PUL. Definitely favorable result among PUL patients. BCBS states that PUL was non-inferior in the BPH6 endpoint. You are correct. It was actually proven SUPERIOR. BCBS states that the evidence does not support the conclusion despite the published fact that the statistical analysis, including and accommodating for the anticipated loss of TURP randomized subjects, does in fact support that conclusion. BCBS gives no scientific reason why they disagree with the science.
3. The analysis states of the LIFT study that there were 9 serious adverse events (SAE) in the PUL arm versus 1 in the sham control and then 16 more in the PUL arm. This is a very misleading statement and should be corrected. Of relevance is simply the number of related SAE. There was 1 related SAE in the first 3 months (an overnight stay related to clot retention for a PUL patient, which outside of a clinical study would not be

No. Yes/No Citations of Missing Evidence

characterized as serious, and certainly is not uncommon for other BPH treatment options) and one thereafter (removal of a bladder stone that formed from smaller bladder calcification confirmed as existing prior to PUL). Please read the text of the Roehrborn article to further understand the adverse event table.

4. Crossover Study: the analysis states that there was no difference in improvement in Qmax after PUL versus after sham. This represents a misunderstanding. After sham, Qmax improved 2ml/s. After PUL, it improved another 2ml/s, showing a cumulative increase of 4ml/s over baseline. A Qmax change of 4ml/s is exactly what was seen in the randomized study for PUL.
5. LIFT Study: The analysis states that the 5-year report showed a difference between ITT and per-protocol results. This is false. Also, the analysis states that the average AUASI improvements were -7.85 ITT versus -10.61 PP. This too is false. The publication shows the following: -7.85 ITT versus -7.56 PP, and as stated in the Discussion section, there was no statistical difference, which effectively shows the small loss to follow-up had no effect on outcomes analysis.
6. LIFT Study: "87 analyzed in CONSORT vs 104 in text." Please remove this statement or clarify. Without explanation, the statement implies an error, rather than a misunderstanding. As explained in the article text, 104 of 140 subjects were available for follow-up and there was a detailed explanation of each of the 36 subjects with missing data. Of the 104, 87 had no surgical retreatment or protocol deviation.
7. LIFT Study Summary: "high loss to follow-up" statement is not warranted when compared to currently covered BPH services. Over 80% of living subjects had available data at 5 years. This is truly unparalleled in the field of BPH studies. Perhaps the BCBSA team is comparing this study to pharmaceutical studies from other disease states, etc. In the context of whether PUL has been studied at least as well, if not better, than currently covered services in BPH, the answer is a definitive "yes".
8. Section Summary: Table 4. I fail to see why treating men who are washed out of medication is "not standard or optimal" when this is true of every other BPH study conducted that supports any covered BPH procedure. Of course, we would not wash patients out of medication to treat them with PUL, but to not do so in a clinical study would create tremendous bias in the data. This is well understood by AUA, NIH, CMS, and FDA.

"Unclear history of BPH treatments" - no patient had undergone a prior BPH procedure in the studies.

"Unclear intended use" - there is no published clinical study of BCBS currently covered BPH services that distinguish between treating men after or before medication usage. As such, it is irrelevant that this is also true of the bibliography supporting PUL.

9. Table 5: "high loss to follow-up/exclusions; only LOCF ITT analysis provided". This statement is again not reflective of the body of evidence supporting BCBS covered services. The fact that LIFT included 74% subjects at 5 years and analyzed both PP and ITT is the very state of the art in BPH - it does not exist in most other currently covered services.
10. Summary of Evidence: please correct these paragraphs with the above mentioned points.
11. Practice Guidelines and Position Statements:
 - AUA - there is no mention that a publicly available position statement exists where AUA states that US patients should have access to PUL, a proven BPH treatment. Please include this.
 - EAU - The European Association of Urology publishes BPH guidelines semi-annually. They rate the PUL clinical evidence as Level 1A on the Oxford score, which is the highest possible rating.
 - Medicare National Coverage - please include/mention that no BPH treatment has ever been reviewed for national coverage determination.

3 No

4 No

Appendix Table 3. Comparison of Studies Included in Systematic Reviews of PUL

Study	Perera (2015)	Shore (2015)	NICE (2015)	Jones (2016)	Jung (2019); Cochrane	Tanneru (2019)
<i>RCTs</i>						
LIFT	●	●	●	●	●	●
BPH6				●	●	●
<i>Noncomparative studies</i>						
Sievert (2019)						●
Bozkurt (2016)				●		
Cantwell (2014)	●	●	●	●		
Shore (2014)	●		●			
Garrido Abad (2013)		●	●			
McNicholas (2013)	●	●	●	●		
Chin (2012)	●	●	●	●		●
Woo (2012)	●	●	●			
Woo (2011)	●		●	●		
Hoffman (2012)	●					

References

1. Sarma AV, Wei JT. Clinical practice. Benign prostatic hyperplasia and lower urinary tract symptoms. *N Engl J Med*. Jul 19 2012; 367(3): 248-57. PMID 22808960
2. Barry MJ, Fowler FJ, O'Leary MP, et al. Measuring disease-specific health status in men with benign prostatic hyperplasia. Measurement Committee of The American Urological Association. *Med Care*. Apr 1995; 33(4 Suppl): AS145-55. PMID 7536866
3. O'leary MP. Validity of the "bother score" in the evaluation and treatment of symptomatic benign prostatic hyperplasia. *Rev Urol*. 2005; 7(1): 1-10. PMID 16985801
4. Djavan B, Marberger M. A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. *Eur Urol*. 1999; 36(1): 1-13. PMID 10364649
5. Foster HE, Barry MJ, Dahm P, et al. Surgical Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline. *J Urol*. Sep 2018; 200(3): 612-619. PMID 29775639
6. Reich O, Gratzke C, Bachmann A, et al. Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients. *J Urol*. Jul 2008; 180(1): 246-9. PMID 18499179
7. Lerner LB, McVary KT, Barry MJ, et al. Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA GUIDELINE PART II-Surgical Evaluation and Treatment. *J Urol*. Oct 2021; 206(4): 818-826. PMID 34384236
8. Sundaram D, Sankaran PK, Raghunath G, et al. Correlation of Prostate Gland Size and Uroflowmetry in Patients with Lower Urinary Tract Symptoms. *J Clin Diagn Res*. May 2017; 11(5): AC01-AC04. PMID 28658743
9. Rosen RC, Catania JA, Althof SE, et al. Development and validation of four-item version of Male Sexual Health Questionnaire to assess ejaculatory dysfunction. *Urology*. May 2007; 69(5): 805-9. PMID 17482908
10. Cappelleri JC, Rosen RC. The Sexual Health Inventory for Men (SHIM): a 5-year review of research and clinical experience. *Int J Impot Res*. 2005; 17(4): 307-19. PMID 15875061
11. Sønksen J, Barber NJ, Speakman MJ, et al. Prospective, randomized, multinational study of prostatic urethral lift versus transurethral resection of the prostate: 12-month results from the BPH6 study. *Eur Urol*. Oct 2015; 68(4): 643-52. PMID 25937539
12. Barry MJ, Williford WO, Chang Y, et al. Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association

- symptom index and the benign prostatic hyperplasia impact index is perceptible to patients? *J Urol.* Nov 1995; 154(5): 1770-4. PMID 7563343
13. Roehrborn CG, Wilson TH, Black LK. Quantifying the contribution of symptom improvement to satisfaction of men with moderate to severe benign prostatic hyperplasia: 4-year data from the CombAT trial. *J Urol.* May 2012; 187(5): 1732-8. PMID 22425127
 14. McVary KT, Roehrborn CG, Avins AL, et al. American Urological Association Guideline: Management of Benign Prostatic Hyperplasia (BPH). 2010 (affirmed 2014); [http://www.auanet.org/guidelines/benign-prostatic-hyperplasia-\(2010-reviewed-and-validity-confirmed-2014\)](http://www.auanet.org/guidelines/benign-prostatic-hyperplasia-(2010-reviewed-and-validity-confirmed-2014)). Accessed July 7, 2023.
 15. Perera M, Roberts MJ, Doi SA, et al. Prostatic urethral lift improves urinary symptoms and flow while preserving sexual function for men with benign prostatic hyperplasia: a systematic review and meta-analysis. *Eur Urol.* Apr 2015; 67(4): 704-13. PMID 25466940
 16. Cantwell AL, Bogache WK, Richardson SF, et al. Multicentre prospective crossover study of the 'prostatic urethral lift' for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. *BJU Int.* Apr 2014; 113(4): 615-22. PMID 24765680
 17. Shore N, Freedman S, Gange S, et al. Prospective multi-center study elucidating patient experience after prostatic urethral lift. *Can J Urol.* Feb 2014; 21(1): 7094-101. PMID 24529008
 18. McNicholas TA, Woo HH, Chin PT, et al. Minimally invasive prostatic urethral lift: surgical technique and multinational experience. *Eur Urol.* Aug 2013; 64(2): 292-9. PMID 23357348
 19. Chin PT, Bolton DM, Jack G, et al. Prostatic urethral lift: two-year results after treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. *Urology.* Jan 2012; 79(1): 5-11. PMID 22202539
 20. Woo HH, Bolton DM, Laborde E, et al. Preservation of sexual function with the prostatic urethral lift: a novel treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. *J Sex Med.* Feb 2012; 9(2): 568-75. PMID 22172161
 21. Woo HH, Chin PT, McNicholas TA, et al. Safety and feasibility of the prostatic urethral lift: a novel, minimally invasive treatment for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). *BJU Int.* Jul 2011; 108(1): 82-8. PMID 21554526
 22. Hoffman RM, Monga M, Elliott SP, et al. Microwave thermotherapy for benign prostatic hyperplasia. *Cochrane Database Syst Rev.* Sep 12 2012; (9): CD004135. PMID 22972068
 23. Roehrborn CG, Gange SN, Shore ND, et al. The prostatic urethral lift for the treatment of lower urinary tract symptoms associated with prostate enlargement due to benign prostatic hyperplasia: the L.I.F.T. Study. *J Urol.* Dec 2013; 190(6): 2161-7. PMID 23764081
 24. Shore N. A Review of the Prostatic Urethral Lift for Lower Urinary Tract Symptoms: Symptom Relief, Flow Improvement, and Preservation of Sexual Function in Men With Benign Prostatic Hyperplasia. *Curr Bladder Dysfunct Rep.* 2015; 10(2): 186-192. PMID 25984251
 25. Roehrborn CG, Rukstalis DB, Barkin J, et al. Three year results of the prostatic urethral L.I.F.T. study. *Can J Urol.* Jun 2015; 22(3): 7772-82. PMID 26068624
 26. McVary KT, Gange SN, Shore ND, et al. Treatment of LUTS secondary to BPH while preserving sexual function: randomized controlled study of prostatic urethral lift. *J Sex Med.* Jan 2014; 11(1): 279-87. PMID 24119101
 27. Garrido Abad P, Coloma Del Peso A, Sinues Ojas B, et al. [Urolift®, a new minimally invasive treatment for patients with low urinary tract symptoms secondary to BPH. Preliminary results]. *Arch Esp Urol.* 2013; 66(6): 584-91. PMID 23985459
 28. Jones P, Rajkumar GN, Rai BP, et al. Medium-term Outcomes of Urolift (Minimum 12 Months Follow-up): Evidence From a Systematic Review. *Urology.* Nov 2016; 97: 20-24. PMID 27208817
 29. Bozkurt A, Karabakan M, Keskin E, et al. Prostatic Urethral Lift: A New Minimally Invasive Treatment for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. *Urol Int.* 2016; 96(2): 202-6. PMID 26613256
 30. Ray A, Morgan H, Wilkes A, et al. The Urolift System for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A NICE Medical Technology Guidance. *Appl Health Econ Health Policy.* Oct 2016; 14(5): 515-26. PMID 26832146

31. Tanneru K, Gautam S, Norez D, et al. Meta-analysis and systematic review of intermediate-term follow-up of prostatic urethral lift for benign prostatic hyperplasia. *Int Urol Nephrol*. Jun 2020; 52(6): 999-1008. PMID 32065331
32. Rukstalis D, Rashid P, Bogache WK, et al. 24-month durability after crossover to the prostatic urethral lift from randomised, blinded sham. *BJU Int*. Oct 2016; 118 Suppl 3: 14-22. PMID 27684483
33. Sievert KD, Schonthaler M, Berges R, et al. Minimally invasive prostatic urethral lift (PUL) efficacious in TURP candidates: a multicenter German evaluation after 2 years. *World J Urol*. Jul 2019; 37(7): 1353-1360. PMID 30283994
34. Jung JH, Reddy B, McCutcheon KA, et al. Prostatic urethral lift for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. *Cochrane Database Syst Rev*. May 25 2019; 5(5): CD012832. PMID 31128077
35. Gratzke C, Barber N, Speakman MJ, et al. Prostatic urethral lift vs transurethral resection of the prostate: 2-year results of the BPH6 prospective, multicentre, randomized study. *BJU Int*. May 2017; 119(5): 767-775. PMID 27862831
36. Franco JVA, Jung JH, Imamura M, et al. Minimally invasive treatments for benign prostatic hyperplasia: a Cochrane network meta-analysis. *BJU Int*. Aug 2022; 130(2): 142-156. PMID 34820997
37. Roehrborn CG. Prostatic Urethral Lift: A Unique Minimally Invasive Surgical Treatment of Male Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. *Urol Clin North Am*. Aug 2016; 43(3): 357-69. PMID 27476128
38. Roehrborn CG, Barkin J, Gange SN, et al. Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study. *Can J Urol*. Jun 2017; 24(3): 8802-8813. PMID 28646935
39. Rukstalis D, Grier D, Stroup SP, et al. Prostatic Urethral Lift (PUL) for obstructive median lobes: 12 month results of the MedLift Study. *Prostate Cancer Prostatic Dis*. Sep 2019; 22(3): 411-419. PMID 30542055
40. Eure G, Rukstalis D, Roehrborn C. Prostatic Urethral Lift for Obstructive Median Lobes: Consistent Results Across Controlled Trial and Real-World Settings. *J Endourol*. Jan 2023; 37(1): 50-59. PMID 35876440
41. Shah BB, Tayon K, Madiraju S, et al. Prostatic Urethral Lift: Does Size Matter?. *J Endourol*. Jul 2018; 32(7): 635-638. PMID 29631445
42. Eure G, Gange S, Walter P, et al. Real-World Evidence of Prostatic Urethral Lift Confirms Pivotal Clinical Study Results: 2-Year Outcomes of a Retrospective Multicenter Study. *J Endourol*. Jul 2019; 33(7): 576-584. PMID 31115257
43. Kaplan SA. Surgical Reintervention Rate after Prostatic Urethral Lift: Systematic Review and Meta-Analysis Involving over 2,000 Patients. *Letter. J Urol*. Mar 2021; 205(3): 939-940. PMID 33393811
44. Miller LE, Chughtai B, Dornbier RA, et al. Surgical Reintervention Rate after Prostatic Urethral Lift: Systematic Review and Meta-Analysis Involving over 2,000 Patients. Reply. *J Urol*. Mar 2021; 205(3): 940-941. PMID 33393812
45. McVary KT, Kaplan SA. A Tower of Babel in Today's Urology: Disagreement in Concepts and Definitions of Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Re-Treatment. *J Urol*. Aug 2020; 204(2): 213-214. PMID 32469261
46. Miller LE, Chughtai B, Dornbier RA, et al. Surgical Reintervention Rate after Prostatic Urethral Lift: Systematic Review and Meta-Analysis Involving over 2,000 Patients. *J Urol*. Nov 2020; 204(5): 1019-1026. PMID 32396049
47. Gaffney CD, Basourakos SP, Al Hussein Al Awamlh B, et al. Adoption, Safety, and Retreatment Rates of Prostatic Urethral Lift for Benign Prostatic Enlargement. *J Urol*. Aug 2021; 206(2): 409-415. PMID 33793296
48. Page T, Veeratterapillay R, Keltie K, et al. Prostatic urethral lift (UroLift): a real-world analysis of outcomes using hospital episodes statistics. *BMC Urol*. Apr 07 2021; 21(1): 55. PMID 33827525
49. National Institute for Health and Care Excellence (NICE). Insertion of prostatic urethral lift implants to treat lower urinary tract symptoms secondary to benign prostatic hyperplasia

[IPG475]. 2014; <https://www.nice.org.uk/guidance/ipg475/chapter/1-recommendations>. Accessed July 7, 2023.

50. National Institute for Health and Care Excellence (NICE). UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia [MTG58]. 2021; <https://www.nice.org.uk/guidance/MTG58>. Accessed July 7, 2023.

Documentation for Clinical Review

Please provide the following documentation:

- History and physical and/or consultation notes including:
 - Documentation of no urinary retention, urinary tract infection, or recent prostatitis (within the past year)
 - Past medical and/or surgical treatment(s) and response(s) (within the past year)
- Laboratory report(s), including prostate gland volume and prostate-specific antigen levels
- Radiology report(s)

Post Service

- Results/reports of tests performed
- Procedure report

Coding

This Policy relates only to the services or supplies described herein. Benefits may vary according to product design; therefore, contract language should be reviewed before applying the terms of the Policy.

The following codes are included below for informational purposes. Inclusion or exclusion of a code(s) does not constitute or imply member coverage or provider reimbursement policy. Policy Statements are intended to provide member coverage information and may include the use of some codes for clarity. The Policy Guidelines section may also provide additional information for how to interpret the Policy Statements and to provide coding guidance in some cases.

Type	Code	Description
CPT®	52441	Cystourethroscopy, with insertion of permanent adjustable transprostatic implant; single implant
	52442	Cystourethroscopy, with insertion of permanent adjustable transprostatic implant; each additional permanent adjustable transprostatic implant (List separately in addition to code for primary procedure)
HCPCS	C9739	Cystourethroscopy, with insertion of transprostatic implant; 1 to 3 implants
	C9740	Cystourethroscopy, with insertion of transprostatic implant; 4 or more implants

Policy History

This section provides a chronological history of the activities, updates and changes that have occurred with this Medical Policy.

Effective Date	Action
04/30/2015	Custom policy
10/01/2016	BCBSA Medical Policy adoption – changed from Custom policy BSC7.07 to BCBSA-based policy 7.01.151 Policy revision without position change
10/01/2017	Policy revision without position change
10/01/2018	Policy revision with position change
12/01/2019	Policy revision without position change
10/01/2023	Policy reactivated. Previously archived from 08/01/2020 to 09/30/2023.

Definitions of Decision Determinations

Medically Necessary: Services that are Medically Necessary include only those which have been established as safe and effective, are furnished under generally accepted professional standards to treat illness, injury or medical condition, and which, as determined by Blue Shield, are: (a) consistent with Blue Shield medical policy; (b) consistent with the symptoms or diagnosis; (c) not furnished primarily for the convenience of the patient, the attending Physician or other provider; (d) furnished at the most appropriate level which can be provided safely and effectively to the patient; and (e) not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of the Member's illness, injury, or disease.

Investigational/Experimental: A treatment, procedure, or drug is investigational when it has not been recognized as safe and effective for use in treating the particular condition in accordance with generally accepted professional medical standards. This includes services where approval by the federal or state governmental is required prior to use, but has not yet been granted.

Split Evaluation: Blue Shield of California/Blue Shield of California Life & Health Insurance Company (Blue Shield) policy review can result in a split evaluation, where a treatment, procedure, or drug will be considered to be investigational for certain indications or conditions, but will be deemed safe and effective for other indications or conditions, and therefore potentially medically necessary in those instances.

Prior Authorization Requirements and Feedback (as applicable to your plan)

Within five days before the actual date of service, the provider must confirm with Blue Shield that the member's health plan coverage is still in effect. Blue Shield reserves the right to revoke an authorization prior to services being rendered based on cancellation of the member's eligibility. Final determination of benefits will be made after review of the claim for limitations or exclusions.

Questions regarding the applicability of this policy should be directed to the Prior Authorization Department at (800) 541-6652, or the Transplant Case Management Department at (800) 637-2066 ext. 3507708 or visit the provider portal at www.blueshieldca.com/provider.

We are interested in receiving feedback relative to developing, adopting, and reviewing criteria for medical policy. Any licensed practitioner who is contracted with Blue Shield of California or Blue Shield of California Promise Health Plan is welcome to provide comments, suggestions, or concerns. Our internal policy committees will receive and take your comments into consideration.

For utilization and medical policy feedback, please send comments to: MedPolicy@blueshieldca.com

Disclaimer: This medical policy is a guide in evaluating the medical necessity of a particular service or treatment. Blue Shield of California may consider published peer-reviewed scientific literature, national guidelines, and local standards of practice in developing its medical policy. Federal and state law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over medical policy and must be considered first in determining covered services. Member contracts may differ in their benefits. Blue Shield reserves the right to review and update policies as appropriate.

Appendix A

POLICY STATEMENT	
BEFORE	AFTER <u>Blue font: Verbiage Changes/Additions</u>
<p>Reactivated Policy</p> <p>Policy Statement: N/A</p>	<p>Prostatic Urethral Lift 7.01.151</p> <p>Policy Statement:</p> <ul style="list-style-type: none"> I. Use of prostatic urethral lift in individuals with moderate-to-severe lower urinary tract obstruction due to benign prostatic hyperplasia may be considered medically necessary when all of the following criteria are met: <ul style="list-style-type: none"> A. The individual has persistent or progressive lower urinary tract symptoms despite medical therapy (α_1-adrenergic antagonists maximally titrated, 5α-reductase inhibitors, or combination medication therapy maximally titrated) over a trial period of no less than 6 months, or is unable to tolerate medical therapy B. Prostate gland volume is less than or equal to 80 mL C. Prostate anatomy demonstrates normal bladder neck without an obstructive or protruding median lobe D. Individual does not have urinary retention related to conditions other than benign prostatic hyperplasia, urinary tract infection, or recent prostatitis (within past year) E. Individual has had appropriate testing to exclude diagnosis of prostate cancer F. Individual does not have a known allergy to nickel, titanium or stainless steel II. Use of prostatic urethral lift in all other situations, including repeat procedures, is considered investigational.